Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Wegovy and Zepbound, two popular weight loss GLP-1 medications, would remain cost-effective at a higher price, according to an Oct. 29 revised report from the Institute for Clinical and Economic ...

There’s no question that medications like semaglutide (Wegovy) and tirzepatide (Zepbound) have been making headlines lately. They’re two of the few injectable medications approved specifically for ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...